FDA ApprovedUnited States
First FDA-Approved Cell Therapy to Reduce Chronic Graft-Versus-Host Disease
TREGZI (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) — donor cell transplant product to help adults with blood cancers stay free of chronic graft-versus-host disease
FDA approval on 30 June 2026 for TREGZI (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) suspension — a donor-matched cell…
This is for adults with blood cancers who need a matched-donor stem cell transplant after intensive…